(MedPage Today) — MADRID — Mavacamten (Camzyos) failed to replicate its previous successes in hypertrophic cardiomyopathy (HCM) when applied to a population with symptomatic, nonobstructive disease, the phase III ODYSSEY-HCM trial showed….
Source link : https://www.medpagetoday.com/meetingcoverage/esc/117243
Author :
Publish date : 2025-08-30 15:20:00
Copyright for syndicated content belongs to the linked Source.
